share_log

Lantern Pharma Analyst Ratings

Benzinga Analyst Ratings ·  Feb 16, 2023 00:03
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
02/15/2023 110.61% EF Hutton → $11 Maintains Buy
11/01/2022 110.61% EF Hutton → $11 Initiates Coverage On → Buy
03/11/2022 589.26% HC Wainwright & Co. $34 → $36 Maintains Buy
11/02/2021 550.97% HC Wainwright & Co. $32 → $34 Maintains Buy
10/07/2021 512.67% HC Wainwright & Co. → $32 Initiates Coverage On → Buy
07/28/2020 359.51% Colliers Securities → $24 Initiates Coverage On → Buy

What is the target price for Lantern Pharma (LTRN)?

The latest price target for Lantern Pharma (NASDAQ: LTRN) was reported by EF Hutton on February 15, 2023. The analyst firm set a price target for $11.00 expecting LTRN to rise to within 12 months (a possible 110.61% upside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Lantern Pharma (LTRN)?

The latest analyst rating for Lantern Pharma (NASDAQ: LTRN) was provided by EF Hutton, and Lantern Pharma maintained their buy rating.

When is the next analyst rating going to be posted or updated for Lantern Pharma (LTRN)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lantern Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lantern Pharma was filed on February 15, 2023 so you should expect the next rating to be made available sometime around February 15, 2024.

Is the Analyst Rating Lantern Pharma (LTRN) correct?

While ratings are subjective and will change, the latest Lantern Pharma (LTRN) rating was a maintained with a price target of $0.00 to $11.00. The current price Lantern Pharma (LTRN) is trading at is $5.22, which is within the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment